Fast-Acting Insulin Analogues vs. Regular Insulin for Type 1 Diabetes

Five faster-acting insulin analogues may provide blood glucose control similar to regular human insulin for people with type 1 diabetes, according to a review of 15 studies involving 6,335 participants. Certain analogues, including ultra-rapid lispro and fast-acting aspart, may also reduce the risk of severe complications such as episodes of low blood glucose.

Type 1 diabetes occurs when the pancreas cannot produce insulin, causing blood sugar levels to become too high. Patients manage the condition through insulin injections to control glucose levels and maintain health.

How do faster-acting insulin analogues work?

Faster-acting insulin analogues are modified versions of human insulin. They’re designed to act more quickly after injection than regular human insulin, allowing patients to inject them immediately before meals to lower blood sugar levels after eating.

Examples of these analogues include insulin lispro, insulin aspart, insulin glulisine, fast-acting insulin aspart (FIAsp), and ultra-rapid lispro insulin (URLi).

Did You Know? HbA1c is the metric used to measure short-term glycaemic control, reflecting a patient’s average blood sugar levels over the previous two to three months.

What are the benefits of these insulin analogues?

The analysis found that five faster-acting analogues may be similar to regular human insulin regarding short-term glycaemic control, defined as a period of less than one year. The participants in these studies were monitored for durations between 24 and 52 weeks.

Some analogues, specifically ultra-rapid lispro and fast-acting aspart, may be more effective at reducing severe hypoglycaemia. They may also reduce the risk of diabetic ketoacidosis, a dangerous complication characterized by high blood sugar and urine ketones.

Expert Insight: Samantha Carter notes that while average glucose control remains similar across these treatments, the potential reduction in severe complications like diabetic ketoacidosis represents a significant clinical distinction for patient safety.

Where is the evidence unclear?

Researchers expressed uncertainty regarding the effects of these analogues on fasting blood glucose levels and mild or moderate episodes of low blood sugar. Evidence was also unclear concerning nocturnal hypoglycaemia, treatment adherence, and health-related quality of life.

NICE 2026 Type 2 Diabetes Guideline – Part 5: Insulin Treatment and Complications

The evidence is current as of May 2025, but researchers noted a lack of data for long-term follow-up exceeding one year.

What limits the current findings?

Confidence in the evidence is limited because most studies were unblinded, meaning participants and healthcare providers knew which treatment was administered. Reporting inconsistencies and a lack of study detail further impacted the results.

Additionally, the studies saw a moderate dropout rate, with between 5% and 20% of participants failing to complete the treatment period.

What may happen next?

Future research could focus on blinded studies to increase confidence in the results. Researchers may also seek data on long-term follow-up beyond the one-year mark to determine if these benefits persist.

Frequently Asked Questions

What are faster-acting insulin analogues?
They are modified versions of human insulin, such as insulin lispro and insulin aspart, designed to work more quickly after injection than regular human insulin.

Do these analogues control blood sugar better than regular insulin?
According to the analysis, five faster-acting analogues may offer similar benefits in short-term blood glucose control as measured by HbA1c.

Can these analogues reduce diabetes complications?
Some analogues, including ultra-rapid lispro and fast-acting aspart, may reduce the risk of severe complications like severe low blood glucose and diabetic ketoacidosis.

How do you typically balance the timing of your insulin injections with your meals?